OncoMatch/Clinical Trials/NCT06219356
A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas
Is NCT06219356 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies GLB-002 for non-hodgkin lymphoma.
Treatment: GLB-002 — Study GLB-002-01 is a first-in-human (FIH), phase 1, open-label, dose escalation and expansion clinical study, the purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of GLB-002 monotherapy in participants with relapsed or refractory Non-Hodgkin lymphomas (R/R NHL).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard of care therapy
who have failed standard of care therapy or lack an effective treatment regimen
Cannot have received: chemotherapy
Receipt of anticancer medications/therapies such as chemotherapy, targeted therapy, immunotherapy, biologic therapy, or herbal agent ≤ 28 days or 5 half-lives, whichever is shorter, prior to the first dose of GLB-002
Cannot have received: targeted therapy
Receipt of anticancer medications/therapies such as chemotherapy, targeted therapy, immunotherapy, biologic therapy, or herbal agent ≤ 28 days or 5 half-lives, whichever is shorter, prior to the first dose of GLB-002
Cannot have received: immunotherapy
Receipt of anticancer medications/therapies such as chemotherapy, targeted therapy, immunotherapy, biologic therapy, or herbal agent ≤ 28 days or 5 half-lives, whichever is shorter, prior to the first dose of GLB-002
Cannot have received: biologic therapy
Receipt of anticancer medications/therapies such as chemotherapy, targeted therapy, immunotherapy, biologic therapy, or herbal agent ≤ 28 days or 5 half-lives, whichever is shorter, prior to the first dose of GLB-002
Cannot have received: herbal agent
Receipt of anticancer medications/therapies such as chemotherapy, targeted therapy, immunotherapy, biologic therapy, or herbal agent ≤ 28 days or 5 half-lives, whichever is shorter, prior to the first dose of GLB-002
Cannot have received: CAR-T cell therapy
chimeric antigen receptor T cell therapy (CAR-T) within 3 months prior to the first dose of GLB-002
Cannot have received: autologous stem cell transplant
Receipt of Autologous Stem Cell Transplantation (ASCT) within the last 3 months
Cannot have received: allogeneic hematopoietic stem cell transplantation
allogeneic hematopoietic stem cell transplantation (allo-HSCT) within the last 6 months prior to the first dose of GLB-002
Lab requirements
Blood counts
Good performance of major organs, including hematology, liver and kidney function, and coagulation. etc.
Kidney function
Good performance of major organs, including hematology, liver and kidney function, and coagulation. etc.
Liver function
Good performance of major organs, including hematology, liver and kidney function, and coagulation. etc.
Cardiac function
impaired cardiac function or clinically significant cardiac disease at current or within last 6 months; QT interval >470 ms
Good performance of major organs, including hematology, liver and kidney function, and coagulation. etc. QT interval >470 milliseconds (ms) using electrocardiographic (ECG) at Screening. impaired cardiac function or clinically significant cardiac disease at current or within last 6 months.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify